Single-Center Retrospective Evaluation of Clinical Features and Life Expectancy in Mid-Range/Reduced Left Ventricular Ejection Fraction Heart Failure Patients Who Died During Hospitalization

Abstract

Today, despite medical developments the frequency of heart failure is increasing. The current guidelines have categorized patients with heart failure (HF) by their phenotypes to better explain them. In our study, we aimed to compare the basic clinical features, drug treatment and the life expectancy in HF phenotypes who died during hospitalization. Material and Methods: 100 consecutive patients who admitted with HF between 2011 and 2018 and died of cardiac cause during last hospitalization were evaluated. Patients with left ventricle ejection fraction (LVEF) 41-49% and N-terminal pro-B type natriuretic peptide (NT-proBNP) level >125 pg/mL were classified in the study as HFmrEF. Patients with EF% ≤40 NT-proBNP level >125 pg/mL were classified in the study as HFrEF. There were 50 patients from each HF group. Patients' demographic features, major laboratory parameters, drug treatments and life expectancy were evaluated in retrospective analysis. SPSS version 17.0 program was used for statistical analysis. p<0.05 was considered statistically significant. Results: The LVEF values of HFrEF and HFmrEF patients were 30% (15-38) and 45% (40-49), respectively. There was no significant difference between groups in drug treatment. The life expectancy values of the groups were 15 (1-61) months in the HFmrEF group and 11 (1-49) months in the HFrEF group (p=0.043). Conclusion: In our study, it was concluded that the demographic characteristics of HFrEF and HFmrEF patients were different. The life expectancy in HFmrEF group was longer than in HFrEF group.